Inflammation and Autoimmunity References:

1. American Academy of Dermatology Association. Eczema types: atopic dermatitis symptoms. https://www.aad.org/public/diseases/eczema/types/atopic-dermatitis/symptoms. Accessed September 11, 2020.

2. Baker BS. The role of microorganisms in atopic dermatitis. *Clin Exp Immunol*. 2006;144(1):1-9.

3. Eichenfield LF, Tom WL, Berger TJ, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. *J Am Acad Dermatol*. 2014;71(1):116-132.

4. Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. *Ann Allergy Asthma Immunol*. 2018;120:10-22.

5. Narla S, Silverberg JI. Association between atopic dermatitis and serious cutaneous, multiorgan and systemic infections in US adults. *Ann Allergy Asthma Immunol*. 2018;120(1):66-72.

6. Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. *Ann Allergy Asthma Immunol*. 2018;121(3):340-347.

7. Silverberg JI, Gelfand JM, Margolis DJ, et al. Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults. *Br J Dermatol*. 2019;181(3):554-565.

8. Silverberg JI, Garg NK, Paller AS, Fishbein AB, Zee PC. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. *J Invest Dermatol*. 2015;135(1):56-66.

9. Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. *Int J Dermatol*. 2012;51(10):1206-1212.

10. Bergqvist C, Ezzedine K. Vitiligo: a review. *Dermatology*. 2020;236:571-592.

11. Gandhi K, Ezzedine K, Anastassopoulos KP, et al. Prevalence of vitiligo among adults in the United States. *JAMA Dermatol*. 2022;158(1):43-50.

12. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Seminar: Vitiligo. *Lancet*. 2015;386:74-84.

13. Frisoli M, Essien K, Harris JE. Vitiligo: mechanisms of pathogenesis and treatment. *Annu Rev Immunol*. 2020;38(1):621-648.

14. Morrison B, Burden-Teh E, Batchelor JM, Mead E, Grindlay D, Ratib S. Quality of life in people with vitiligo: a systematic review and meta-analysis. *Br J Dermatol*. 2017;177(6):e338-e339.

15. Silverberg JI, Silverberg NB. Association between vitiligo extent and distribution and quality-of-life impairment. *JAMA Dermatol*. 2013;149(2):159-164.

16. Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis. *J Eur Acad Dermatol Venereol*. 2018;32(8):1343-1351.

17. Alavi A, Hamzavi I, Brown K, et al. Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies. *Br J Dermatol*. 2022;186(5):803-813.

18. Naik HB, Paul M, Cohen SR, Alavi A, Suàrez-Fariñas M, Lowes MA. Distribution of self-reported hidradenitis suppurativa age at onset. *JAMA Dermatol*. 2019;155(8):971-973.

19. Ocker L, Rached NA, Seifert C, Scheel C, Bechara FG. Current medical and surgical treatment of hidradenitis suppurativa—a comprehensive review. *J Clin Med*. 2022;11(23):7240.